|Bid||103.58 x 0|
|Ask||103.89 x 0|
|Day's range||102.95 - 102.95|
|52-week range||89.82 - 124.70|
|PE ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||N/A|
Shares of Celgene (CELG) plunged to the bottom of the S&P 500 today after the drug maker abandoned clinical trials testing its experimental drug Mongersen as a treatment for Crohn’s disease. The stock fell almost 10.8% to close at $121.33 on a day when the S&P 500 posted a 0.5% gain, making Celgene the worst-performing stock in the index. Mongersen was a high-profile drug in Celgene’s pipeline.
Stocks that moved substantially or traded heavily Friday: Celgene Corp., down $14.63 to $121.33 The drugmaker ended late-stage testing of a potential treatment for Crohn's disease. General Electric Co., ...
NEW YORK, Oct (Shenzhen: 000069.SZ - news) 20 (Reuters) - World stocks advanced, bond yields rose and the U.S. dollar strengthened on Friday on increased hopes President Donald Trump could make progress on his fiscal plans after the U.S. Senate approved a budget blueprint that paves the way for tax cuts. U.S. Republican Senator Rand Paul appeared to back the administration's sweeping tax cut plan, saying he was "all in" for massive tax cuts, even as the Senate passed a key budget measure without his support one day earlier.
BMO Capital Markets’ M. Ian Somaiya takes a look at the biotech sector on Friday, writing that another strong quarter could help the stocks keep climbing. Somaiya writes that he expects solid results from ...
Celgene’s (CELG) efforts to reduce its dependence on the blood cancer drug Revlimid suffered a setback today when the drug maker Celgene said it would abandon testing mongersen, a big treatment for Crohn’s disease. The drug maker announced that it would stop two trials, and would not initiate a third study following a risk-benefit analysis by a data monitoring committee. Celgene says there were “no meaningful safety imbalances” identified in the committee’s analysis.
Stocks look set for a higher open this morning after the Senate passed a budget resolution that could clear the way for tax cuts. S&P 500 futures have, while Dow Jones Industrial futures have. Nasdaq Composite ...
Celgene Corp. was downgraded to neutral at Baird Equity Research on Friday after the drugmaker abandoned three Crohn's disease drug trials late Thursday. Baird analyst Brian Skorney also lowered the company's ...
Celgene announced that after consulting the data safety and monitoring committee that was overseeing the main mongersen study, called REVOLVE, it had decided to stop developing the drug. It cited a futility analysis, implying the medicine was not effective, but said there were no safety problems.
Celgene Corp. shares dropped in the extended session Thursday after the biotech company said it would discontinue two clinical trials for a Crohn's disease treatment and not start a third. Celgene shares ...
Celgene Corporation today announced that the GED-0301 phase III REVOLVE trial in Crohn’s disease and the extension trial will discontinue.
Celgene Corporation today announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 and 5 receptor modulator, in relapsing multiple sclerosis were accepted for the MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting, which is being held in Paris, October 25-28, 2017.
SUMMIT, N.J.--(BUSINESSWIRE)-- Ozanimod highlighted in two oral presentations detailing results from phase III SUNBEAM ™ and RADIANCE ™ trials in RMS Additional clinical and non-clinical poster presentations ...
Celgene Corporation today announced that phase 2 data of investigational compound ozanimod in Crohn’s disease and ulcerative colitis will be presented at the World Congress of Gastroenterology at ACG2017 in Orlando.
Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.
In the past 3 weeks, MannKind has tripled to $6.75, bringing the year-to-date return on Nate Pile's fund to 34.82%. Here's what's behind MannKind's strong gains and what Nate is doing about it.
Navient (NAVI) was the biggest loser amid the S&P 500 on October 5. Navient started the week on a weaker note and traded weakly for the first three trading days.
Morgan Stanley's Matthew Harrison and his team take a look at biotech today, writing that investors should buy Biogen (BIIB) rather than Celgene (CELG). Harrison upgraded Biogen to Overweight from Equal Weight, and raised his price target from $311 to $375, writing that the company's base business is more durable than he anticipated, as its multiple sclerosis treatment, Ocrevus, is losing market share more slowly than expected. In addition, he sees Spinraza, Biogen's spinal muscular atrophy drug, as worth potentially $4 billion, a fact that's under-appreciated by the market, and writes that the company's Alzheimer's business "remains the key, must-own catalyst.
Stocks look set for a higher open today ahead of U.S. jobless claims data this morning. S&P 500 futures have ticked up 0.1%, while Dow Jones Industrial Average futures are little changed. Nasdaq Composite ...
Nimbus and Celgene announced a significant partnership focused on autoimmune and inflammatory diseases. Here are the three unique elements of the Nimbus model.
Celgene Corporation will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results.
Celgene doesn’t let a partner down. The biotech on Monday bought 750,000 more shares of Acceleron (XLRN) for $28 million in a public stock offering. Celgene (CELG) remains Acceleron’s largest holder and is a partner for the latter’s lead program, Luspatercept, and for sotatercept.
BOUDRY, Switzerland--(BUSINESSWIRE)-- Multiple presentations evaluate the investigational uses of ABRAXANE alone or as combination therapy to treat non-small cell lung cancer and as combination therapy ...